Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response…
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf…
Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
-- Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy in Pediatric and Adult…
Copyright © 2025 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design